Alcon Inc. Stock News

It's rare to find a high-growth foreign company that isn't stuck in a big downtrend. While ALC shares are down sharply year-on-year, its valuation is not so bad considering impressive EPS growth.

Alcon Inc. (NYSE:ALC ) Q3 2022 Earnings Conference Call November 16, 2022 8:00 AM ET Company Participants Dan Cravens - Vice President and Global Head, Investor Relations David Endicott - Chief Execut

Given the supply chain challenges, unfavorable foreign exchange impact and inflationary pressure, Alcon (ALC) reduces its core EPS and net sales expectations for 2022.

Alcon has continued in a downtrend since September 2021 with persistent mean reversion activity across this time. With FY22 guidance narrowed and macro-headwinds prevailing, forward-looking multiples

Most investors would probably be pleased with a share price gain of 33% in just over three years, but more than 50% sounds a lot better.

New Jersey-based biotech firm Aerie is seeing its shares move higher amid news of it being bought by Aerie Pharmaceuticals.

Alcon will buy glaucoma drugs maker Aerie Pharmaceuticals in a $770 million deal that sent the biotech stock flying Tuesday. The post Blistering-Hot Biotech Shopping Spree Continues: Alcon To Buy Aeri

Alcon agrees to acquire Aerie, the ophthalmic therapies company, for $15.25 a share.

Alcon's (ALC) robust innovation pipeline is delivering solid results as evidenced by the successful launch of new ATIOL roles and SiHy contact lenses.

Alcon Inc. (NYSE:ALC ) Q2 2022 Results Conference Call August 10, 2022 8:00 AM ET Company Participants Dan Cravens - VP and Global Head IR David Endicott - CEO Tim Stonesifer - CFO Conference Call Par

Despite bearing the brunt of inflationary pressure across both Total Surgical and Vision Care franchises, Alcon (ALC) succeeds in mitigating much of the impact through cost-improvement efforts.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Investors are optimistic about Alcon's (ALC) better-than-expected results and robust performance across its popular franchises.

Investors are optimistic about Alcon's (ALC) better-than-expected results and robust performance across its popular franchises.

Alcon continues to grow at a double-digit rate and is on track to achieve management's full-year guidance. Both the Surgical and the Vision Care segments delivered double-digit growth, which highligh